Otsuka gets exclusive rights to oncolytic virus therapy from Takara Bio; License Agreement Terminated
Otsuka Pharmaceutical Co. Ltd. licensed exclusive Japanese rights to develop and sell Takara Bio Inc.’s oncolytic virus therapy as a potential cancer treatment.
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.